董事会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2025-030 烟台正海生物科技股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）第四届董事会第八次 会议于 2025 年 8 月 4 日以通讯方式召开，会议通知已于 2025 年 7 月 24 日以电 子邮件形式向全体董事发出，本次会议应参会董事 8 人，实参会董事 8 人（其中 独立董事李江华先生因工作原因无法出席会议，委托独立董事宋希亮先生代为出 席会议并行使表决权，其中以通讯表决方式出席会议的人数为 7 人，分别为郭焕 祥、董群、宋侃、赵丽、张超、宋希亮、王辉）。会议由郭焕祥先生主持，监事 许月莉、潘励山、宋广平列席会议。会议出席人数、召开和表决方式符合《公司 法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 经与会董事研究，会议审议通过了如下决议： 1、关于 2025 年半年度报告全文及其摘要的议案 公司《2025 年半年度报告全文》及《 ...

智通财经APP讯，正海生物(300653.SZ)发布2025年半年度报告，该公司营业收入为1.88亿元，同比减少 5.14%。归属于上市公司股东的净利润为4648.57万元，同比减少45.97%。归属于上市公司股东的扣除非 经常性损益的净利润为4028.07万元，同比减少46.77%。基本每股收益为0.26元。 ...

正海生物公告，2025年上半年营业收入1.88亿元，同比下降5.14%。净利润4648.57万元，同比下降 45.97%。 ...

烟台正海生物科技股份有限公司 烟台正海生物科技股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025-029 【2025 年 8 月 5 日】 1 烟台正海生物科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人郭焕祥、主管会计工作负责人赵丽及会计机构负责人(会计主 管人员)赵丽声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 1、成长性风险 公司专注于再生医学相关产品的研发及产业化，以自主创新的核心技术 开发出的口腔修复膜和脑膜产品，是目前公司业务收入的主要来源，两款产 品的良好口碑和不断扩大的品牌影响力使其在临床应用上获得了越来越广泛 的赞誉，同时也逐步感受到市场环境变化、竞争加剧等因素带来的压力和挑 战。公司结合市场需求及自身技术积淀，相继启动了钙硅生物陶瓷骨修复材 料、宫腔修复膜、乳房补片、人脐带间充质干细胞等新产品的梯队研发，并 在基因工程、 ...

Core Viewpoint - Zhenghai Biological has experienced significant shareholder reductions despite its ongoing growth and strong financial performance, raising concerns about market confidence and future stability [1][4][8]. Shareholder Reduction - The controlling shareholder, Mi Bohai, has reduced his stake by 5% from August 5 to February 3, resulting in a decrease from 42.53% to 37.53% [7]. - Longwood, the second-largest shareholder, has also been reducing its holdings, with its stake dropping to 9.27% [7]. - Together, the two major shareholders have cashed out approximately 5.77 billion yuan, with Mi Bohai realizing about 3.70 billion yuan and Longwood about 2.07 billion yuan [7][8]. Financial Performance - Zhenghai Biological has shown consistent revenue and net profit growth since 2013, with a projected annual revenue of 3.38 billion yuan and a net profit of 1.31 billion yuan for 2020, reflecting a growth rate of around 20% [2]. - The company reported revenue of 216 million yuan and net profit of 95 million yuan for the first three quarters of 2020, marking year-on-year increases of 7.39% and 19.74%, respectively [1][2]. Business Model and Product Offering - Zhenghai Biological specializes in the research, development, production, and sales of biological regenerative materials, including oral and skin repair membranes, and bone repair materials [2]. - The company maintains a high gross margin exceeding 90% since 2012, attributed to its advanced technology [2][3]. Market Challenges - The company faced unprecedented challenges during the COVID-19 pandemic, particularly in its core business areas such as oral and neurosurgery, which were significantly impacted [2].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhenghai Biological, which has a current PE ratio of 33.40, significantly lower than the industry average of 55.41 [1][2] - Zhenghai Biological's market capitalization stands at 4.037 billion yuan, with a total of 16,966 shareholders as of March 31, 2025, indicating a slight decrease in shareholder numbers [1] - The company specializes in the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes and absorbable dura mater patches [1] Group 2 - The latest financial report for the first quarter of 2025 shows that Zhenghai Biological achieved a revenue of 97.42 million yuan, representing an 8.68% year-on-year increase, while net profit decreased by 34.06% to 26.63 million yuan [1] - The gross profit margin for the company is reported at 80.96%, indicating strong profitability despite the decline in net profit [1] - Zhenghai Biological has been recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023, reflecting its industry standing and innovation capabilities [1]

最新一期业绩显示，2025年一季报，公司实现营业收入9741.58万元，同比8.68%；净利润2662.67万 元，同比-34.06%，销售毛利率80.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13正海生物32.2828.984.2639.02亿行业平均 53.5248.844.67111.58亿行业中值37.1437.112.5651.72亿1九安医疗10.9411.060.86184.59亿2英科医疗 12.7713.771.14201.84亿3新华医疗15.2014.091.2497.43亿4奥美医疗15.9515.631.6457.63亿5山东药玻 15.9516.001.83150.91亿6振德医疗16.0515.131.0258.27亿7康德莱16.5816.591.3735.73亿8九强生物 17.0215.832.0984.31亿9奥泰生物17.6018.561.4256.13亿10维力医疗17.8218.532.0940.65亿11三鑫医疗 19.1519.163.1543.57亿12安图生物19.3418.462.48220.51亿 资金流向方面，7月23日，正海生物 ...

Core Insights - Zhenghai Biological's stock closed at 21.19 yuan, up 1.29%, with a rolling PE ratio of 31.55, marking a 64-day low, and a total market capitalization of 3.814 billion yuan [1] - The average PE ratio in the medical device industry is 51.87, with a median of 37.48, placing Zhenghai Biological at 67th in the industry ranking [1] - The company experienced a net outflow of 1.9014 million yuan in principal funds on July 16, with a total outflow of 12.4302 million yuan over the past five days [1] Company Overview - Zhenghai Biological focuses on the research, production, and sales of biological regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, and surgical sponges [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023 [1] Financial Performance - In the first quarter of 2025, Zhenghai Biological reported revenue of 97.4158 million yuan, a year-on-year increase of 8.68%, while net profit was 26.6267 million yuan, reflecting a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

Core Insights - The Chinese dental beauty industry is experiencing rapid growth, driven by increasing consumer demand for oral health and aesthetics, with a market size expected to exceed 78.5 billion yuan by 2025 [1][16][25] - The industry is characterized by three main features: explosive demand from 718 million oral disease patients, innovation in supply with a 25% penetration rate of invisible orthodontics, and rapid market expansion with a CAGR of 15.9% from 2018 to 2023 [1][12][16] Industry Overview - Dental beauty focuses on improving the appearance, shape, and alignment of teeth through non-invasive or minimally invasive techniques, aiming to unify natural aesthetics and functionality [2] - The industry includes various segments such as teeth whitening, veneer restoration, crown restoration, orthodontics, and gum shaping [2] Development Drivers - **Consumer Upgrade and Demand Change**: The shift from essential treatment to aesthetic consumption is evident, with over 60% of Gen Z viewing teeth whitening as key to confidence [4][16] - **Technological Innovation**: Breakthroughs in materials science and digital technology are reshaping industry standards, with AI aesthetic design and 3D printing significantly enhancing service efficiency [6][25] - **Policy and Capital Synergy**: Government initiatives like "Healthy China 2030" and increased financing are facilitating industry growth and standardization [7][25] - **Silver Economy and Niche Market Rise**: The aging population is driving demand for dental aesthetics, with 35% of spending on implants and aesthetic restorations coming from those aged 50 and above [8][25] Industry Chain - The industry chain exhibits high collaboration and vertical integration, with upstream focusing on high-value consumables and digital equipment, while domestic brands are rapidly replacing foreign ones in the mid-range market [9][20] Market Size and Growth - The market size grew from 28.56 billion yuan in 2018 to 59.82 billion yuan in 2023, with a projected growth to over 78.5 billion yuan by 2025 [16][18] Competitive Landscape - The industry features a multi-tiered competition structure, with foreign brands dominating the high-end market and domestic brands rapidly expanding in the mid-range and low-end markets [20][22] - The top five brands in the implant sector hold nearly 70% market share, while the invisible orthodontics market is dominated by two major players [20][22] Future Trends - **Technological Integration**: The industry is moving towards full-cycle intelligent management, integrating AI, 3D printing, and biological materials [25][26] - **Market Layering and Downstream Expansion**: The competition is characterized by high-end precision, mid-range differentiation, and low-end accessibility, with community health stations expanding rapidly [27][28] - **Ecosystem Reconstruction and Regulatory Upgrades**: The industry is evolving towards a cross-sector integration of healthcare, technology, and consumer services, with increased regulatory oversight [28]

Company Overview - Zhenghai Biological's closing price on July 8 was 20.85 yuan, up 1.21%, with a rolling PE ratio of 31.05, marking a new low in 58 days, and a total market capitalization of 3.753 billion yuan [1] - The company ranks 67th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1] Shareholder Information - As of March 31, 2025, Zhenghai Biological had 16,966 shareholders, a decrease of 193 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Focus - Zhenghai Biological specializes in the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, skin repair membranes, surgical packing sponges, self-etching adhesives, active biological bone, dura mater patches, phosphoric acid etchants, and dental pit and fissure sealants [1] Industry Recognition - The company was included in the 2023 list of leading new material enterprises in Shandong Province, recognized as one of the top 50 new material enterprises [1] Financial Performance - In the first quarter of 2025, Zhenghai Biological reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, and a net profit of 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]